Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.
Mansour N, Heinrich K, Zhang D, Winkelmann M, Ingenerf M, Gold L, Klambauer K, Rudelius M, Klauschen F, von Bergwelt-Baildon M, Ricke J, Heinemann V, Westphalen CB, Kunz WG.
Mansour N, et al. Among authors: zhang d.
Cancer Imaging. 2024 Jun 7;24(1):70. doi: 10.1186/s40644-024-00708-5.
Cancer Imaging. 2024.
PMID: 38849902